$13.63
1.56% today
Nasdaq, Dec 30, 10:00 pm CET
ISIN
US62855J1043
Symbol
MYGN

Myriad Genetics, Inc. Target price 2024 - Analyst rating & recommendation

Myriad Genetics, Inc. Classifications & Recommendation:

Buy
38%
Hold
38%
Sell
25%

Myriad Genetics, Inc. Price Target

Target Price $21.63
Price $13.63
Potential
Number of Estimates 16
16 Analysts have issued a price target Myriad Genetics, Inc. 2025 . The average Myriad Genetics, Inc. target price is $21.63. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 16 analysts: 6 Analysts recommend Myriad Genetics, Inc. to buy, 6 to hold and 4 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Myriad Genetics, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Myriad Genetics, Inc. stock at Buy or hold.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 753.20 840.47
11.03% 11.59%
EBITDA Margin -9.48% 4.39%
19.31% 146.31%
Net Margin -38.42% -11.13%
106.06% 71.03%

16 Analysts have issued a sales forecast Myriad Genetics, Inc. 2024 . The average Myriad Genetics, Inc. sales estimate is

$840m
Unlock
. This is
2.05% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$845m 2.60%
Unlock
, the lowest is
$838m 1.71%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $753m 11.03%
2024
$840m 11.59%
Unlock
2025
$882m 4.92%
Unlock
2026
$962m 9.11%
Unlock
2027
$1.0b 5.45%
Unlock
2028
$1.1b 3.90%
Unlock

12 Analysts have issued an Myriad Genetics, Inc. EBITDA forecast 2024. The average Myriad Genetics, Inc. EBITDA estimate is

$36.9m
Unlock
. This is
188.13% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$39.2m 193.48%
Unlock
, the lowest is
$28.9m 168.97%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-71.4m 32.47%
2024
$36.9m 151.72%
Unlock
2025
$38.1m 3.12%
Unlock
2026
$72.8m 91.17%
Unlock
2027
$117m 61.08%
Unlock
2028
$163m 39.02%
Unlock

EBITDA Margin

2023 -9.48% 19.31%
2024
4.39% 146.31%
Unlock
2025
4.32% 1.59%
Unlock
2026
7.57% 75.23%
Unlock
2027
11.56% 52.71%
Unlock
2028
15.46% 33.74%
Unlock

9 Myriad Genetics, Inc. Analysts have issued a net profit forecast 2024. The average Myriad Genetics, Inc. net profit estimate is

$-93.5m
Unlock
. This is
20.94% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-45.5m 61.54%
Unlock
, the lowest is
$-112m 5.38%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-289m 128.78%
2024
$-93.5m 67.68%
Unlock
2025
$-44.6m 52.37%
Unlock
2026
$-7.7m 82.72%
Unlock
2027
$16.4m 312.73%
Unlock
2028
$42.3m 158.36%
Unlock

Net Margin

2023 -38.42% 106.06%
2024
-11.13% 71.03%
Unlock
2025
-5.05% 54.63%
Unlock
2026
-0.80% 84.16%
Unlock
2027
1.61% 301.25%
Unlock
2028
4.01% 149.07%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -3.18 -1.03
128.78% 67.61%
P/E negative
EV/Sales 1.51

9 Analysts have issued a Myriad Genetics, Inc. forecast for earnings per share. The average Myriad Genetics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.03
Unlock
. This is
20.77% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.50 61.54%
Unlock
, the lowest is
$-1.23 5.38%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-3.18 128.78%
2024
$-1.03 67.61%
Unlock
2025
$-0.49 52.43%
Unlock
2026
$-0.08 83.67%
Unlock
2027
$0.18 325.00%
Unlock
2028
$0.47 161.11%
Unlock

P/E ratio

Current -10.32 70.86%
2024
-13.06 26.55%
Unlock
2025
-27.41 109.88%
Unlock
2026
-158.57 478.51%
Unlock
2027
74.56 147.02%
Unlock
2028
28.86 61.29%
Unlock

Based on analysts' sales estimates for 2024, the Myriad Genetics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.54 36.63%
2024
1.51 2.27%
Unlock
2025
1.43 4.69%
Unlock
2026
1.31 8.34%
Unlock
2027
1.25 5.17%
Unlock
2028
1.20 3.75%
Unlock

P/S ratio

Current 1.48 34.71%
2024
1.45 2.01%
Unlock
2025
1.39 4.69%
Unlock
2026
1.27 8.34%
Unlock
2027
1.20 5.17%
Unlock
2028
1.16 3.75%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today